The NICE Reference Case Requirement: Implications for Drug Manufacturers and Health Systems

Author： Langley P.C.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.22, Iss.4, 2004-01, pp. : 267-271

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The NICE Reference Case Requirement: More Pain for What, if Any, Gain?

By Gafni A.   Birch S.  

PharmacoEconomics, Vol. 22, Iss. 4, 2004-01 ,pp. : 271-273

Adis International

Access to resources Recommend Favorite

Reference drug-pricing systems in Europe

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 320, 2001-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

The National Institute for Health and Clinical Excellence (NICE) and Drug Treatment for Alzheimer's Disease

By Iliffe Steve  

CNS Drugs, Vol. 21, Iss. 3, 2007-01 ,pp. : 177-184

Adis International

Access to resources Recommend Favorite

Systems Biology of Apoptosis and Survival: Implications for Drug Development

By  

Current Pharmaceutical Design, Vol. 17, Iss. 3, 2011-01 ,pp. : 190-203

Bentham Science Publishers

Access to resources Recommend Favorite

The use of evidence in pharmacovigilance: Case reports as the reference source for drug withdrawals

By Arnaiz J.A.   Carné X.   Riba N.   Codina C.   Ribas J.   Trilla A.  

European Journal of Clinical Pharmacology, Vol. 57, Iss. 1, 2001-04 ,pp. : 89-91

Springer Publishing Company

Access to resources Recommend Favorite